Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVETUX-HN: 2 versus 4 cycles of cetuximab + avelumab + cisplatin + docetaxel in recurrent/metastatic head and neck cancer
2025-521738-27-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, avelumab, cisplatin and docetaxel in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Quality of life regarding role functioning. Planned start Nov 2025; status: authorised.
02
Drugs
cetuximabavelumabcisplatindocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-521738-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521738-27-00.